🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

27 recruiting trials

for Moderate to Severe Chronic Obstructive Pulmonary Disease

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease NCT06531798Phase 46 sites📍 Bangalore📍 Dalgate, Drugjan📍 Hyderabad AstraZeneca · Tests: Breztri Aerosphere Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation NCT06959095Phase 3281 sites📍 Bakersfield📍 Modesto📍 Newport Beach GlaxoSmithKline · Tests: Depemokimab, Placebo Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo NCT07069829n/a36 sites📍 Buenos Aires📍 La Plata📍 Mar del Plata AstraZeneca A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) NCT07116031Phase 235 sites📍 Los Angeles📍 Washington D.C.📍 Atlanta Sanofi · Tests: Belumosudil, Belumosudil A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) NCT07759245Phase 2127 sites📍 Birmingham📍 Newport Beach📍 San Diego Eli Lilly and Company · Tests: Brenipatide, Placebo, Standard of Care A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease NCT07082738Phase 2367 sites📍 Birmingham📍 Glendale📍 Phoenix AstraZeneca · Tests: AZD6793, Placebo This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization NCT07587658Phase 41 site📍 Mullica Hill Regeneron Pharmaceuticals · Tests: dupilumab, Placebo Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) NCT06961214Phase 3193 sites📍 Sheffield📍 Aurora📍 Brooksville GlaxoSmithKline · Tests: Depemokimab, Placebo A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis NCT07725939Phase 213 sites📍 Miami📍 Rincon📍 Columbus UCB Biopharma SRL · Tests: Galvokimig, Placebo A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease NCT05896800NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Inhaled nitric oxide (NO), air A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) NCT06883305Phase 3305 sites📍 Foley📍 Mobile📍 Sheffield AstraZeneca · Tests: Tezepelumab, Placebo Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease NCT06072690n/a1 site📍 Kaunas Lithuanian University of Health Sciences Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells NCT06491043Phase 22 sites📍 New Taipei City📍 Taoyuan City Meribank Biotech Co., Ltd. · Tests: UMC119-06-05 A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) NCT07780669Phase 32 sites📍 Doral📍 Lake Charles GlaxoSmithKline · Tests: GSK5784283, Placebo, Standard of care A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD NCT07668518Phase 1, Phase 23 sites📍 Charlestown📍 Sydney📍 Camberwell Kither Biotech Srl · Tests: KIT2014, Placebo A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) NCT06878261Phase 3284 sites📍 Birmingham📍 Cullman📍 Phoenix AstraZeneca · Tests: Tezepelumab, Placebo A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07640451Phase 21 site📍 Shanghai Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: HRS-9821 Inhalation Suspension, HRS-9821 Placebo Inhalation Suspension Phase II Study of RC1416 Injection in COPD NCT07402551Phase 246 sites📍 Hefei📍 Suzhou📍 Chongqing Nanjing RegeneCore Biotech Co., Ltd. · Tests: RC1416, RC1416 Placebo A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07418736Phase 21 site📍 Beijing CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Tests: CM326 dose 1, CM326 dose 2, Placebo A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease NCT06300320Phase 212 sites📍 Hefei📍 Lanzhou📍 Guangzhou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ05105 tablets Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease NCT07464587Phase 354 sites📍 Chizhou📍 Hefei📍 Chongqing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQC3721 Suspension for Inhalation A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease NCT07382258NA1 site📍 Nanjing Novlead Inc. · Tests: Nitric Oxide Generation and Delivery System A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD NCT07351734Phase 21 site📍 Guangzhou Joincare Pharmaceutical Group Industry Co., Ltd · Tests: JKN2403 Tablets, Placebo A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07363694Phase 2, Phase 3189 sites📍 Birmingham📍 Dothan📍 Mobile Pfizer · Tests: PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3 Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07039669Phase 34 sites📍 Beijing📍 Shenzhen📍 Nanjing Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 611, Placebo A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2) NCT07780656Phase 34 sites📍 Miami📍 Tampa📍 Rapid City GlaxoSmithKline · Tests: GSK5784283, Placebo, Standard of care A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) NCT07646587Phase 232 sites📍 Los Angeles📍 Jacksonville📍 Miami Lakes Windward Bio · Tests: WIN378, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy